MUC1 and neoplasm: As a clinical indication for this obstacle to vaccine efficacy, in the trial evaluating the TG4010 Muc-1 vaccine in lung cancer only patients whose tumor expressed low levels of PD-L1 had a marked benefit in progression-free survival (56).